Sam Pearce stepped into the newly created position of Jazz Chief Commercial Officer in August 2024, bringing with her an established track record of effectively scaling commercial operations to achieve transformational growth and accelerate patient access to medicines across geographies. One hundred days in, Sam shares her initial experiences and vision for the future of her role and Jazz.

Developmental and Epileptic Encephalopathies (DEEs) are a group of rare and severe epilepsies which are characterized by seizures and significant developmental delays. Most DEEs begin in early life, often in infancy, with children experiencing frequent and severe seizures, which can be of multiple types. This generates a complex clinical picture in which both developmental abnormalities and severe epilepsy contribute to the functional impairment of these children which continues into adulthood.

In this video, watch Mat Davis, PhD, Vice President, Head of Data Science, Evidence and Value Generation, discuss how we leverage focused and integrated quantitative methods in our R&D process to transform patient lives.

Establishing expert consensus treatment recommendations is imperative to providing more people with consistent care. As a leader in neuroscience, we are committed to empowering those we serve through innovative science and thoughtful real-world evidence.

As we continue to make advancements in cancer research, we’re focused on delivering treatment options in areas of oncology with high unmet needs, including HER2-positive biliary tract cancer (BTC), as well as supporting patient communities beyond R&D. Through recent advocacy efforts, in addition to sharing new data at the upcoming ASCO 2024 Annual Meeting, we’re committed to supporting patients throughout their disease journeys.

Through our commitment to patients with unmet needs, we’re raising awareness about HER2-positive biliary tract cancer (BTC), an aggressive type of cancer often associated with a poor prognosis. As we continue to focus on those for whom we can have the greatest impact, HER2-positive cancers are one area we’re applying the science by investigating and developing innovative solutions for patients.